Nephrology and urology disorders are common complications of cardiovascular diseases and diabetes. Certain drugs and unhealthy food habits are also known to cause nephrological and urological diseases. According to the National Institute of Diabetes and Digestive & Kidney Diseases approximately 26 million individuals in the U.S. suffer from chronic kidney diseases. Statistics also shows that about 87,000 patients die of kidney failure every year. Some of the commonly used drug classes for treating nephrological and urological disorders include diuretics, anti-hypertensive drugs, phosphate binders, and anti-cholinergic drugs, and 5-alpha-reductase inhibitors. Anticholinergic drugs block the action of acetylcholine, a chemical messenger that sends signals to brain and eventually triggers abnormal bladder contractions associated with overactive bladder. Acetylcholine controls several functions of the body that are not under voluntary control such as sweating, pupil dilation, contraction of bladder muscles, digestion, and salivation. With regard to nephrological and urological disorders, anticholinergic drugs are mostly used for treating overactive bladder.
Anticholinergic drugs are recommended for a wide range of conditions including overactive bladder, Parkinson’s disease, chronic obstructive pulmonary disease, vomiting, nausea, psychosis, and depression. Certain drugs such as oxybutynin and hyoscine are prescribed for their anticholinergic effect. Others exhibit anticholinergic activity not related to their primary mode of action, for example, ranitidine and carbamazepine. Increasing prevalence of neurological disorders drives the global anticholinergic drugs market. However, there has been keen interest in the harm caused by drugs with anticholinergic effect. Certain side-effects of these drugs such as dry mouth, constipation, blurry vision, sedation, decreased sweating, difficulty urinating, decreased saliva, and memory impairment restrain the global anticholinergic drugs market.
The global market for anticholinergic drugs, especially those used in nephrology and urology, is expected to expand at a moderate pace from 2017 to 2025. Some of the commonly prescribed anticholinergic drugs are Detrol (tolterodine) by Pfizer, Enablex (darifenacin) by Actavis, Vesicare (solifenacin) by Astellas Pharma US, Inc., Sanctura (trospium) by Allergan, Toviaz (fesoterodine) by Pfizer, and Ditropan XL (oxybutynin) by Janssen Pharmaceuticals. Recently, in July 2014, a research study conducted by the University of East Anglia revealed that long-term use of anticholinergic drugs could impact common physical functions of the patient.
The global anticholinergic drugs market can be segmented based on drugs into natural and synthetic or semisynthetic drugs. Natural anticholinergic drugs include Atropine and Hyoscine (Scopolamine). Based on mechanism of action, the global anticholinergic drugs market can be segmented into mydriatic, anti-spasmodic, anti-parkinson, anti-ulcer, anti-asthmatic, pre-anesthetic, drugs for motion sickness, and drugs for urinary incontinence. Based on distribution channel, the global anticholinergic drugs market can be segmented into hospital pharmacies, clinics, hospitals, retail pharmacies, and online pharmacies.
Geographically, the global anticholinergic drugs market can be segmented into five major regions: North America, Europe, Asia Pacific (APAC), Latin America, and Middle East & Africa. Asia Pacific held the leading market share, followed by North America, in 2016. These two regions are expected to retain their positions from 2017 to 2025. Rising prevalence of neurological complications and increasing government initiatives that appear to be moving toward shorter periods of patent exclusivity for new drug applications are some of the factors driving the market in these regions. Moreover, large population, increasing disposable income, and growing awareness among patients are a few factors driving the market in Asia Pacific. Europe and Middle East & Africa are likely to present significant growth opportunities to the anticholinergic drugs market during the forecast period. This is attributable to increasing geriatric population in these regions.
Key players operating in the global anticholinergic drugs market are Pfizer, Inc., Astellas Pharma US, Inc., Allergan plc, and Janssen Pharmaceuticals (a Johnson & Johnson company).
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.